Terms: = Bone cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
521 results:
1. Hsc70 promotes anti-tumor immunity by targeting pd-l1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract] [Full Text] [Related]
2. Correlations between the modification patterns mediated by pyroptosis-related genes, tumor microenvironment, and immunotherapy in soft tissue sarcoma.
Cai Y; Meng J; Qiu Y; Huang X; Du H; Yao J
Medicine (Baltimore); 2024 May; 103(20):e38173. PubMed ID: 38758862
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Favorable impact of PD1/pd-l1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T; Chittilappilly C; Pirich T; Neuditschko B; Hackner K; Lind J; Aksoy O; Graichen U; Klee S; Herzog F; Wiesner C; Errhalt P; Pecherstorfer M; Podar K; Vallet S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702145
[TBL] [Abstract] [Full Text] [Related]
6. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
7. New advances in the treatment of chondrosarcoma under the PD-1/pd-l1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract] [Full Text] [Related]
8. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract] [Full Text] [Related]
9. NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.
Ji R; Wang Y; Pan D; Han J; Wang Y; Zheng S; Zhao W; Li X; Han C; Zhang L
Cancer Lett; 2024 Jun; 591():216893. PubMed ID: 38636892
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
11. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma.
Cao J; Zhu C; Cao Z; Ke X
Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118
[TBL] [Abstract] [Full Text] [Related]
12. Visual analysis of bone malignancies immunotherapy: A bibliometric analysis from 2010 to 2023.
Shen K; Yang L; Ke S; Gao W
Medicine (Baltimore); 2024 Mar; 103(13):e37269. PubMed ID: 38552042
[TBL] [Abstract] [Full Text] [Related]
13. Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy.
Shor D; Louie AV; Zeng KL; Menjak IB; Atenafu EG; Chia-Lin Tseng ; Detsky J; Larouche J; Zhang B; Soliman H; Myrehaug S; Maralani P; Hwang DM; Sahgal A; Chen H
J Neurooncol; 2024 Apr; 167(2):275-283. PubMed ID: 38526757
[TBL] [Abstract] [Full Text] [Related]
14. [Efficacy of combined treatment with pirfenidone and pd-l1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract] [Full Text] [Related]
16. Large-scale bioreactor production of extracellular vesicles from mesenchymal stromal cells for treatment of acute radiation syndrome.
Kink JA; Bellio MA; Forsberg MH; Lobo A; Thickens AS; Lewis BM; Ong IM; Khan A; Capitini CM; Hematti P
Stem Cell Res Ther; 2024 Mar; 15(1):72. PubMed ID: 38475968
[TBL] [Abstract] [Full Text] [Related]
17. [Adenocarcinoma with Aplastic Anemia as an Immune-related Adverse Event Caused by Pembrolizumab: Report of a Case].
Hashimoto S; Haga N; Morimoto M; Doi Y
Kyobu Geka; 2024 Mar; 77(3):235-238. PubMed ID: 38465499
[TBL] [Abstract] [Full Text] [Related]
18. EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome.
Kato S; Hamada M; Okamoto A; Yamashita D; Miyoshi H; Arai H; Satou A; Gion Y; Sato Y; Tsuyuki Y; Miyata-Takata T; Takata K; Asano N; Takahashi E; Ohshima K; Tomita A; Hosoda W; Nakamura S; Okuno Y
Blood Adv; 2024 May; 8(9):2138-2147. PubMed ID: 38429084
[TBL] [Abstract] [Full Text] [Related]
19. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates pd-l1 blockade in melanoma.
Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
[TBL] [Abstract] [Full Text] [Related]
20. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
[Next]
